Table 1 : Clinical characteristics of study patients by CKD stage.


  All stages Stage 3 Stage 4 Stage 5 p-value

Number of patients 120 40 40 40  --
Male/female 70:50 27:13 25:15 18:22 Ns
Age (yrs)(mean) 46.73±14.18 44.68±15.22 47.38±14.39 48.05±12.96 Ns
Duration of CKD(yrs) 2.98±1.47 2.25±1.19 3.23±1.49 3.48±1.46 <0.001
eGFR[mean] (ml/min/1.73m2) 24.16±12.17 39.21±16.48 21.30±3.75 11.98±1.73 <0.0001
Serum creatinine (mg/dl)[mean] 3.27±1.34 1.85±0.24 3.12±0.54 4.83±0.73 <0.0001
S.B.P.(mmHg) 135.60±11.80 135.38±12.24 135.05±11.52 136.38±11.90 Ns
D.B.P.( mmHg) 83.16±6.87 83.55±6.99 82.35±7.30 83.58±6.39 Ns
On any anti-hypertensive (%) 80.83% 72.5% 80% 90% Ns
H/O CAD (%) 39.16% 32.5% 37.5% 47.5% Ns
H/O Smoking(%) 31% 35% 30% 27.5% Ns
Diabetes mellitus (%) 40% 37.5% 37.5% 45% Ns
BSA (m2) [mean] 1.61±0.11 1.60±0.11 1.62±0.12 1.62±0.11 Ns
LVMI (g/m2)[mean] 134.92±21.71 126 ±   14.62 131.65±16.61 147.10±26.54 <0.0001
LVH;LVMI>125g/m2(%) 60% 55% 57.5% 67.5% Ns
BMI (kg/m2)[mean] 22.68±2.48 22.20±2.01 22.99±2.85 22.84±2.50 Ns
Hemoglobulin (g/dl) 10.80±1.44 11.22±1.38 10.83±1.34 10.34±1.51 0.024
Intact PTH (pg/ml) 154.03±82.78 87.85±25.27 149.28±51.74 224.98±88.97 <0.0001
Ca x PO4 product (mg/dl)2 54.90±3.85 53.20±4.12 54.69±3.63 54.80±3.86 Ns
Serum cholesterol(mg/dl) 167.10±43.89 174.80±43.60 155.90±41.50 170.60±45.31 Ns
Patients on statins(%) 48.33% 42.5% 50% 52.5% Ns
Plasma NT-proBNP(pg/ml) 585.68±514.84 350.30±277.34 613.35±561.51 793.40±560.98 <0.0001
Serum cTnT>.01,ng/ml (%) 40% 22.5% 37.5% 60% 0.002
Serum hs-CRP (mg/L) 5.96±2.52 5.91±2.68 5.94±2.62 5.99±2.31 Ns
Spot UACR(mg/g of creatinine) 719.37±411.36 394.58±261.43 740.43±366.39 1023.10±332.39 <0.0001

SBP: systolic blood pressure; DBP: diastolic blood pressure; H/O: history of; CAD: coronary artery disease;
BSA: body surface area; LVMI: left ventricular mass index; LVH: left ventricular hypertrophy; BMI: body mass index;
PTH: paratharmone; Ns: not significant

Sathi et al.Clinical Nephrology and Urology Science  2014 1:4DOI : 10.7243/2054-7161-1-4